For those reasons, an FOBs regime would create a "patent protection gap" that would allow a follow-on manufacturer to elude
an innovator's patents while still relying on the innovator's product to bypass the full regulatory process.
Greenwood remarked that a 14-year exclusivity period for biologics would be consistent with previous Congressional efforts
to protect the pharmaceutical industry. "Given that Congress has previously concluded that up to 14 years of patent protection
is appropriate for drugs and biologic products, any statutory formula that allows for follow-on biologics should allow for
at least the same degree of effective market protection," Greenwood said in a prepared statement.
Data exclusivity is particularly important for the biotechnology industry, BIO observes, because the industry is composed
mainly of small companies with unstable funding. The organization notes that these companies would be vulnerable to follow-on
biologics legislation that could change investment incentives.
FDA Issues Guidance for Testing for DEG-Contaminated Glycerin
Rockville, MD (May 1)—The US Food and Drug Administration (
http://www.fda.gov/) issued a guidance to alert pharmaceutical manufacturers, pharmacy compounders, repackers, and suppliers to the potential
public health hazard of glycerin contaminated with diethylene glycol (DEG), a poison.
FDA has received and continues to receive (most recently in October 2006) reports about fatal DEG poisoning of consumers who
ingested medicinal syrups such as cough syrup or acetaminophen syrup that were manufactured with DEG-contaminated glycerin.
The guidance provides recommendations to help pharmaceutical manufacturers, repackers, other suppliers of glycerin, and pharmacists
who engage in drug compounding avoid using glycerin that is contaminated with DEG and prevent incidents of DEG poisoning.
To avoid using DEG-contaminated glycerin, FDA advises that certain analytical testing procedures be performed on all lots
of glycerin. These tests include a specific identity test that incorporates a limit test for DEG on all containers of all
lots of glycerin before the glycerin is used in the manufacture or preparation of drug products.
The relevant safety limit for DEG is 0.1%, as recognized by the United States Pharmacopeia (USP) monograph for glycerin.
FDA recommends that a manufacturer perform the identity tests, including the limit test for DEG, which appears in the USP
monograph for glycerin. Alternatively, a manufacturer may use an equivalent identification procedure that includes a test
to detect and quantify DEG, provided it meets the relevant safety limit. One alternative procedure is a thin-layer chromatography
method published in the Journal of AOAC International.
FDA also advises that drug-product manufacturers know their supply chain for glycerin, including the manufacturer of the component
and any subsequent distributors. The agency advises that all personnel in pharmaceutical manufacturing facilities, especially
personnel directly responsible for the receipt, testing, and release of glycerin, should be made aware of the importance of
proper testing and the potential hazards if the testing is not done.
The guidance further urges repackers and others who distribute and prepare glycerin for use in drug products to test glycerin
that is used, sold for use, or intended for use in drug products. FDA also recommends that pharmacies that use glycerin in
compounding drug products either test the glycerin for DEG content or ensure that such testing was properly done by a reliable
supplier. In addition, FDA says that bulk or repackaged glycerin intended for use as an excipient or other component of a
drug product should be tested for DEG content following good manufacturing practices.
-Patricia Van Arnum